Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NBTY

This article was originally published in The Tan Sheet

Executive Summary

Global Health Sciences acquisition provides much needed manufacturing capability and $100 mil. in yearly revenue, company says after transaction's close May 25. NBTY's sports nutrition, meal replacement and diet products expected to get a boost from $40 mil. deal; GHS' sports nutrition and weight control lines fall under its Omni-Pak business, while its D&F subsidiary produces herbals, vitamins and minerals. GHS adds 400,000 sq. ft. in facilities to NBTY's continuing operations. NBTY says it plans to keep GHS' operations intact rather than integrating (1"The Tan Sheet" April 30, p. 13)

You may also be interested in...



NBTY Doubles Down: All Divisions Produce Double-Digit Sales Growth In Q1

NBTY is concentrating on improving operational efficiencies and minimizing expansion of its Vitamin World stores as the firm's U.S. retail business inches closer to profitability

NBTY Doubles Down: All Divisions Produce Double-Digit Sales Growth In Q1

NBTY is concentrating on improving operational efficiencies and minimizing expansion of its Vitamin World stores as the firm's U.S. retail business inches closer to profitability

NBTY Doubles Down: All Divisions Produce Double-Digit Sales Growth In Q1

NBTY is concentrating on improving operational efficiencies and minimizing expansion of its Vitamin World stores as the firm's U.S. retail business inches closer to profitability

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092596

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel